Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 113,994,352
  • Shares Outstanding, K 735,400
  • Annual Sales, $ 22,991 M
  • Annual Income, $ 7,722 M
  • 36-Month Beta 1.28
  • Price/Sales 4.97
  • Price/Cash Flow 10.62
  • Price/Book 3.73

Price Performance

See More
Period Period Low Period High Performance
1-Month
152.16 +1.87%
on 05/23/17
164.82 -5.95%
on 05/04/17
-9.60 (-5.83%)
since 04/26/17
3-Month
152.16 +1.87%
on 05/23/17
184.21 -15.85%
on 03/15/17
-19.55 (-11.20%)
since 02/24/17
52-Week
133.64 +15.99%
on 11/04/16
184.21 -15.85%
on 03/15/17
-0.54 (-0.35%)
since 05/26/16

Most Recent Stories

More News
SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Amgen Inc. and Encourages Investors with Losses to Contact the Firm

Khang & Khang LLP (the "Firm") announces that it is investigating claims against Amgen Inc. ("Amgen" or the "Company") (Nasdaq: AMGN) concerning possible violations of federal securities...

AMGN : 155.01 (-0.27%)
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Amgen Inc. Investors

Glancy Prongay & Murray LLP ("GPM") is investigating potential claims on behalf of investors of Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) concerning the Company and its...

AMGN : 155.01 (-0.27%)
Pfizer's Epogen Biosimilar Gets Positive FDA Committee Vote

Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.

JNJ : 126.92 (-0.48%)
MRK : 64.92 (-0.18%)
AMGN : 155.01 (-0.27%)
PFE : 32.14 (-0.06%)
The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene

The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene

CELG : 116.78 (+0.03%)
REGN : 455.17 (-0.12%)
AMGN : 155.01 (-0.27%)
Radius Health Osteoporosis Drug Positive in Phase III Study

Radius Health, Inc. (RDUS) announced positive data from the ACTIVExtend study on Tymlos demonstrating significant reduction (84%) in the incidence of new vertebral fractures compared to placebo when dosed...

RDUS : 34.93 (-3.51%)
MRK : 64.92 (-0.18%)
LLY : 78.05 (-0.37%)
AMGN : 155.01 (-0.27%)
Merck's (MRK) Keytruda Gets FDA Nod for Solid Tumor Cancers

Merck & Co., Inc. (MRK) announced that Keytruda, has received accelerated approval for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors .

MRK : 64.92 (-0.18%)
LLY : 78.05 (-0.37%)
AMGN : 155.01 (-0.27%)
GSK : 42.67 (+0.23%)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amgen Inc. (AMGN)

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amgen, Inc. ("Amgen" or the "Company") (NASDAQ: AMGN). Such investors are encouraged...

AMGN : 155.01 (-0.27%)
Today's Research Reports on Stocks to Watch: Radius Health and Biocept Inc.

NEW YORK, NY / ACCESSWIRE / May 23, 2017 / Amgen's bad day has turned into a winning victory for Radius. Radius' shares rallied after it was revealed that rival Amgen's osteoporosis drug candidate could...

BIOC : 1.51 (+4.14%)
RDUS : 34.93 (-3.51%)
AMGN : 155.01 (-0.27%)
Deloitte Debuts ConvergeHEALTH Evidence Lifecycle Management Solutions that Support Shift to Value Based, Personalized Health Care at 2017 Bio-IT World Conference

This year at the 2017 Bio-IT World Conference & Expo, Deloitte will be showcasing the latest updates to its ConvergeHEALTH suite of life sciences end-to-end evidence lifecycle management solutions, as...

AMGN : 155.01 (-0.27%)
Asian shares drift as blast in Manchester rattles investors

TOKYO (AP) — Asian shares were mostly higher in early trading Tuesday after police said they were treating an explosion in Manchester, England, that killed at least 19 people as a terror attack. Oil...

HUN : 24.75 (-0.44%)
LMT : 283.65 (+0.56%)
CSCO : 31.50 (+0.19%)
F : 10.93 (+0.64%)
AMGN : 155.01 (-0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Support & Resistance

2nd Resistance Point 156.65
1st Resistance Point 155.83
Last Price 155.01
1st Support Level 154.49
2nd Support Level 153.97

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.